VVOS Vivos Therapeutics

Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems

Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems

New Collaboration to Increase Payer Reimbursements and Patient Access

LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance is a natural one as both companies currently operate successful independent medical billing platforms focused on sleep and breathing disorders.

The agreement between Vivos and Nexus effectively combines Vivos’ proprietary out-of-network Billing Intelligence Service with the Nexus’ in-network medical billing platform to create what is expected to be one of the most comprehensive medical billing services in the dental industry. This collaboration is expected to provide both companies’ provider networks with greater access to both in or out-of-network billing with all major medical insurance companies, facilitating case acceptances, insurance billing procedures and reimbursement.

“For a long time, medical billing has been a barrier to wide acceptance of dental offices treating breathing and sleep disorders, which is why we have historically offered fee-based out-of-network claims assistance to Vivos providers and their patients,” said Kirk Huntsman, Vivos Chairman and CEO. “Our Billing Intelligence Service currently achieves a 98% success rate for reimbursement on out-of-network oral appliance claims, which is extremely high. This new relationship will now give Vivos-trained dentists immediate access to some of the highest in-network reimbursement rates in the industry, allowing higher case acceptance for Vivos-trained providers. We believe this will create immediate additional revenue opportunities, not only for Vivos, but for providers within each network, while patients pay less out of pocket expenses.”

“We are excited to partner with Vivos on this initiative which leverages the strengths of each organizations’ medical billing platform by providing access to in-network insurance coverage for our providers and their patients,” said Brett Brocki, Founder of Nexus Dental Systems. “This relationship will allow Nexus additional opportunities to significantly grow our revenue by partnering with such an established, highly successful medical billing platform. We also look forward to sharing The Vivos Method with the over 2,000 dentists in our network.”

Both companies also look forward to exploring further collaboration opportunities associated with Academy of Sleep Disorder Disciplines (ACSDD), dental universities, existing dental service organization relationships, the Veterans Administration and Department of Defense.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution. It has proven effective in over 31,000 patients treated worldwide by more than 1,650 trained dentists.

The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.

For more information, visit .

About Nexus Dental Systems

Nexus Dental Systems is the only company in the market with a true end-to-end billing solution for dental practices. Nexus has the business-to-business expertise to fulfill the needs of a dental practice to Identify, Screen, Treat and Monitor Sleep Treatment Compliance for Oral Appliance Therapy. Nexus’ mission is to raise public awareness of sleep apnea, train dentists to implement dental sleep medicine, create sleep apnea programs for the industry, and connect patients with providers by creating sustainable and resilient systems for providers and the public.

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim,” “expect,” “may,” “could," “should”, “expect,” “project,” “intend,” “plan,” “believe,” “predict,” “anticipates,” “hopeful,” “estimate” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company’s control. Actual results (including, without limitation, the anticipated results of the Company’s agreement with Nexus and the impact of such agreement on the Company’s revenues and results of operations) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors relating to the Company and its business described in the Company’s filings with the Securities and Exchange Commission (“SEC”). The Company’s filings can be obtained free of charge on the SEC’s website at Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Vivos Investor Relations Contact:

Julie Gannon

Investor Relations Officer

720-442-8113

Vivos Media Relations Contact:

Amy Cook

Public Relations Officer

949-813-0182



EN
15/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vivos Therapeutics

 PRESS RELEASE

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Im...

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep Apnea LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, inclu...

 PRESS RELEASE

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediat...

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSA LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective prop...

 PRESS RELEASE

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and P...

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effec...

 PRESS RELEASE

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial ...

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), tod...

 PRESS RELEASE

Vivos Therapeutics Adds to Management Team to Support Expansion and Gr...

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth Two Key Hires Add Significant Experience and Strengthen Vivos’ Ability to Scale Its Promising New Sleep Testing Center and Direct Patient Treatment Operations LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integrat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch